Metrics as of 10/17/2026, 09:25 AM (Berlin time), refresh in progress.
Acumen Pharmaceuticals Stock
Acumen Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Daniel J. O'Connell
- Employees
- 61
- Market cap
- $122 M
- IPO
- 01/07/2021
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular…
Acumen Pharmaceuticals stock: price history
1D
+1.2%
1W
-21.0%
1M
-35.2%
6M
-40.1%
YTD
-19.9%
1Y
-20.7%
2Y
-29.3%
5Y
-87.5%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~12% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Acumen Pharmaceuticals
Analyst assessment of Acumen Pharmaceuticals
PRICE TARGET LOW
US$7.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$7.00
0
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 16/09/2026
Acumen Pharmaceuticals stock metrics
P/E
-1.03
P/B
2.13
EV/EBITDA
-0.94
RETURN ON EQUITY
-57.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.55
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
85.4%
FLOAT SHARES
61,755,720
AVG. DAILY VOLUME (30D)
549,431
Insider transactions (SEC)
Porter Derrell
Porter Derrell
Porter Derrell
Porter Derrell
Porter Derrell
Institutional holders
Comparable stocks
Frequently asked questions about Acumen Pharmaceuticals stock
What does Acumen Pharmaceuticals do?
Acumen Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Daniel J. O'Connell, the company employs around 61 people.
The IPO was on 01/07/2021; the stock trades on NASDAQ under the ticker ABOS.
What do analysts say about Acumen Pharmaceuticals stock?
8 analysts rate the stock, the consensus is Buy (as of 16/09/2026).
The average price target is US$7.00, ranging from US$7.00 to US$7.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
When does Acumen Pharmaceuticals report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 12% stronger than usual.
Does Acumen Pharmaceuticals pay a dividend?
No, Acumen Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Acumen Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Acumen Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Acumen Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.